Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides – NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs

By /

NanoViricides, Inc. reports that the clinical trial of its broad-spectrum antiviral drug NV-CoV-2 is progressing satisfactorily.

Scroll to Top